Biotech hVIVO expanding clinical trial capacity

hVIVO plc, a leading CRO, collaborated with Shionogi for a successful Phase 2a RSV antiviral trial. Positive results show significant reduction in viral load.

hVIVO, a leader in pharmaceutical services, recently expanded its European footprint with the acquisition of two clinical trial units in Germany.

hVIVO plc partners with Inhalon Biopharma, Inc. to test inhaled IN-002 antiviral candidate using RSV Human Challenge Model. Trial set to commence in H2 2026.

hVIVO plc has acquired two Clinical Research Units from CRS, boosting its capabilities in conducting human challenge clinical trials and expanding services.

Explore the innovative world of field studies with FluCamp, revolutionising clinical research by bringing trials closer to real-life scenarios.

hVIVO plc partners with ILiAD Biotechnologies for Phase 3 trial of Bordetella pertussis vaccine, marking a significant milestone in preventing whooping cough.

hVIVO pioneers infectious disease research with successful hMPV study.

hVIVO plc, a leading CRO specializing in infectious disease testing, announces a £2.7m virology lab contract with a US biotech client.

The importance of diversity in clinical trials cannot be overstated. Addressing gaps in representation is crucial for accurate and inclusive medical research.

hVIVO plc (LON: HVO) has successfully completed a pilot study for its hMPV challenge model, paving the way for new vaccines and antivirals.

hVIVO supports UK Health Security Agency’s advice on hand hygiene to combat seasonal illnesses. Learn more about their vital role in public health here.

Discover how hVIVO Group’s innovative approach to human challenge trials and infectious disease expertise has shaped the future of pharmaceutical research in 2024.

hVIVO secures £11.5 million contract to test RSV drug candidate, highlighting the importance of human challenge models in addressing infectious diseases.

Host response biomarkers to viral infections have significant potential in clinical applications, such as guiding diagnostic decisions, reducing unnecessary antibiotic use, and triggering infection control protocols or antiviral treatments. Research on these biomarkers has largely focused

Human viral challenge studies have become essential in evaluating the effectiveness of vaccines, treatments, and prophylactics, providing quicker results compared to larger Phase 2a/b field trials. hVIVO has developed various challenge agents for human use, including

hVIVO plc (LON: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed an £11.5 million contract with

Multiplex PCR plays a crucial role in screening participants for human challenge studies and isolating new viruses, enhancing the integrity of research.